SCHEMBL8520815

SCHEMBL8520815

CC(O)C(NCCO)S(=O)(=O)O

nearest known ligand 0.31

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GRIA1 P42261 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28141623 0.80 TP53 (0.41) MEN1ALDH1A1KMT2A
SCHEMBL356352 0.79 CA2 (0.43) MEN1ALDH1A1KMT2A
SCHEMBL9178677 0.79 CA2 (0.43) MEN1ALDH1A1KMT2A
SCHEMBL9176403 0.79 CA2 (0.43) MEN1ALDH1A1KMT2A
SCHEMBL9177001 0.79 CA2 (0.43) MEN1ALDH1A1KMT2A
SCHEMBL6228290 0.77 MEN1 (0.33) MEN1KMT2A
SCHEMBL2869288 0.76 GRIA1 (0.33) MEN1USP2ALDH1A1MAPTKMT2A
SCHEMBL16670350 0.73
SCHEMBL11142806 0.73 LMNA (0.35) MEN1USP2ALDH1A1MAPTKMT2A
SCHEMBL6241228 0.72 PPARG (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159605-A1 HUMAN INTERFERON-BETA VARIANT WITH DOUBLE MUTATION AND METHOD FOR IMPROVING STABILITY OF HUMAN INTERFERON-BETA VARIANT ABION INC. (KR) 2023-05-25 US claimed
EP-4144748-A1 HUMAN INTERFERON-BETA VARIANT WITH DOUBLE MUTATION AND METHOD FOR IMPROVING STABILITY OF HUMAN INTERFERON-BETA VARIANT Abion Inc. (KR) 2023-03-08 EP claimed
US-5716847-A PHOSPHATE BUFFER-FREE SOLUTION CONTAINING ZWITTERIONIC AMINE BUFFER; STORAGE STABILITY Simmons, Maxine Helen (NZ) 1998-02-10 US claimed
CN-117530943-A Formulations for administration of efluromithine 奥巴斯治疗股份有限公司 2024-02-09 CN disclosed
US-20230159605-A1 HUMAN INTERFERON-BETA VARIANT WITH DOUBLE MUTATION AND METHOD FOR IMPROVING STABILITY OF HUMAN INTERFERON-BETA VARIANT ABION INC. (KR) 2023-05-25 US disclosed
EP-4144748-A1 HUMAN INTERFERON-BETA VARIANT WITH DOUBLE MUTATION AND METHOD FOR IMPROVING STABILITY OF HUMAN INTERFERON-BETA VARIANT Abion Inc. (KR) 2023-03-08 EP disclosed
CN-111433364-A Metabolic engineering of E.coli for biosynthesis of cannabinoid products 因美制药公司 2020-07-17 CN disclosed
CN-109689045-A Purposes of the topical formulations of cannboid in treatment epidermolysis bollosa and Related connective tissue illness 因美制药公司 2019-04-26 CN disclosed
CN-106456662-A Compositions of pentosan polysulfate for oral administration and methods of use thereof 奥利金制药公司 2017-02-22 CN disclosed
EP-0603831-B1 Stable single liquid reagent for the determination of carbon dioxide in serum MEDICAL ANALYSIS SYSTEMS INC (US) 1999-11-10 EP disclosed
US-5849166-A Electrophoresis of nucleic acid fragments AMERSHAM LIFE SCIENCE, INC. (US) 1998-12-15 US disclosed
US-5830642-A IN PRESENCE OF A BUFFER AMERSHAM LIFE SCIENCE, INC. (US) 1998-11-03 US disclosed